Invectys
Developing innovative approaches to immunotherapy to treat cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $4.0m | Debt |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 277 % | (46 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (937 %) | (72 %) | (302 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (713 %) | (51 %) | (254 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Invectys is a biopharmaceutical company founded in 2010 by Pierre Langlade Demoyen and Simon Wain-Hobson, focused on the development of immunotherapy approaches for cancer treatment.
Pierre Langlade Demoyen, who serves as the CEO, has a background in immunology and has been involved in the development of therapeutic vaccines. Simon Wain-Hobson is a virologist and a member of the French Academy of Sciences, bringing extensive research experience to the company. Their combined expertise in immunology and virology forms the foundation of Invectys' scientific approach.
The company's core technology revolves around telomerase, an enzyme that is overexpressed in most cancer cells. Invectys is developing therapeutic vaccines that stimulate the immune system to recognize and attack cancer cells that express telomerase. This approach aims to provide a broadly applicable treatment for various types of cancer.
Invectys has developed a platform of products, including DNA-based vaccines, which are designed to trigger a cellular immune response against tumors. The company is advancing its product candidates through clinical trials to evaluate their safety and efficacy in cancer patients.
The business operates in the oncology market, a segment of the healthcare industry with a high demand for new treatment options. Invectys' business model is centered on the research and development of its proprietary technology, with the goal of commercializing its therapeutic vaccines through partnerships with larger pharmaceutical companies or by bringing them to market independently. The company has secured funding from private investors to support its research and clinical development activities.
Keywords: immunotherapy, oncology, cancer treatment, therapeutic vaccines, telomerase, clinical trials, biopharmaceutical, DNA vaccines, healthcare, immunology